Current treatment options for benign prostatic hyperplasia and their impact on sexual function

Urology

Volumn 61, Issue 4, 2003, Pages 692-698

  Larson, Thayne R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; PAPAVERINE; PHENTOLAMINE; PRAZOSIN; TAMSULOSIN; TERAZOSIN;

CLINICAL TRIAL; DISEASE EXACERBATION; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; IMPOTENCE; INTERMETHOD COMPARISON; LASER COAGULATION; LIBIDO DISORDER; MINIMALLY INVASIVE SURGERY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; SEXUAL FUNCTION; SKIN INCISION; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

EID: 0037381296     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02552-9     Document Type: Review

References (53)

1. Da Silva F.C. Benign prostatic hyperplasia natural evolution versus medical treatment. Eur Urol. 32:(suppl 2):1997;34-37.
2. Oesterling J.E. Benign prostatic hyperplasia a review of its histogenesis and natural history. Prostate Suppl. 6:1996;67-73.
3. Namasivayam S., Minhas S., Brooke J., et al. The evaluation of sexual function in men presenting with symptomatic benign prostatic hyperplasia. Br J Urol. 82:1998;842-846.
4. Schou J., Holm N.R., Meyhoff H.H. Sexual function in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol Suppl. 179:1996;119-122.
5. Tubaro A., Polito M., Giambroni L., et al. Sexual function in patients with LUTS suggestive of BPH. Eur Urol. 40:(suppl 1):2001;19-22.
6. Rosen R, O'Leary M, Altwein J: LUTS and male sexual dysfunction: the Multi-national Survey of the Aging Male (MSAM-7) (abstract). American Urological Association Annual Meeting, Orlando, Florida, May 26, 2002.
7. Calais Da Silva F., Marquis P., Deschaseaux P., et al. Relative importance of sexuality and quality of life in patients with prostatic symptoms results of an international study. Eur Urol. 31:1997;272-280.
8. Blute M.L., Larson T.R., Hanson K.A., et al. Current status of transurethral thermotherapy at the Mayo Clinic. Mayo Clin Proc. 73:1998;597-602.
9. Benign Prostatic Hyperplasia, 5th ed. United Kingdom, Health Publication Ltd, 2001.
10. Rosen R.C., Riley A., Wagner G., et al. The International Index of Erectile Function (IIEF) a multidimensional scale for assessment of erectile dysfunction. Urology. 49:1997;822-830.
11. O'Leary M.P., Fowler F.J., Lenderking W.R., et al. A brief male sexual function inventory for urology. Urology. 46:1995;697-706.
12. Donovan J.L., Abrams P., Peters T.J., et al. The ICS-BPH Study the psychometric validity and reliability of the ICSmale questionnaire. Br J Urol. 77:1996;554-562.
13. Schou J., Poulsen A.L., Nordling J. The value of a new symptom score (DAN-PSS) in diagnosing uro-dynamic infravesical obstruction in BPH. Scand J Urol Nephrol. 27:1993;489-492.
14. Marquis P., Marrel A. Reproducibility and clinical and concurrent validity of the MSF-4 a four-item male sexual function questionnaire for patients with benign prostatic hyperplasia. Value Health. 4:2001;335-343.
15. Leliefeld H.H., Stoevelaar H.J., McDonnell J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJU Int. 89:2002;208-213.
16. Cooper K.L., McKiernan J.M., Kaplan S.A. α-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs. 57:1999;9-17.
17. 1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol. 161:1999;635-640.
18. Lepor H., Tang R., Kobayashi S., et al. Localization of the α1A-adrenoceptor in the human prostate. J Urol. 154:1995;2096-2099.
19. Goldstein I., Carson C., Rosen R., et al. Vasomax for the treatment of male erectile dysfunction. World J Urol. 19:2001;51-56.
20. Traish A., Kim N.N., Moreland R.B., et al. Role of alpha adrenergic receptors in erectile function. Int J Impot Res. 12:(suppl 1):2000;S48-S63.
21. Andersson K.E., Stief C.G. Neurotransmission and the contraction and relaxation of penile erectile tissues. World J Urol. 15:1997;14-20.
22. Debruyne F.M.J., Jardin A., Colloi D., et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol. 34:1998;169-175.
23. Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 335:1996;533-539.
24. Höfner K., Claes H., De Reijke T.M., et al. Tamsulosin 0.4 mg once daily effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 36:1999;335-341.
25. Debruyne F.M.J. Alpha blockers are all created equal? Urology. 56:(suppl 5A):2000;20-22.
26. Prescribing information: Flomax® (tamsulosin hydrochloride) capsules. Physicians' Desk Reference. Montvale, NJ, Medical Economics, 2002, pp 974-977.
27. Narayan P., Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology. 57:2001;466-470.
28. Lukacs B., Grange J.C., Comet D. One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. Urology. 55:2000;540-546.
29. Roehrborn C.G. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology. 58:2001;953-959.
30. van Kerrebroeck P., Jardin A., Laval K.U., et al. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol. 37:2000;306-313.
31. Kirby R.S., Andersen M., Gratzke P., et al. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int. 87:2001;192-200.
32. Zentgraf M., Baccouche M., Jünemann K.P. Diagnosis and therapy of erectile dysfunction using papaverine and phentolamine. Urol Int. 43:1988;65-75.
33. 1-adrenoceptor antagonists prazosin, terazosin, doxazosin, and tamsulosin. J Korean Med Sci. 14:1999;69-74.
34. Clifford G.M., Farmer R.D. Medical therapy for benign prostatic hyperplasia a review of the literature. Eur Urol. 38:2000;2-19.
35. Uygur M.C., Gür E., Arik A.I., et al. Erectile dysfunction following treatments of benign prostatic hyperplasia a prospective study. Andrologia. 30:1998;5-10.
36. Uygur M.C., Arik A.I., Altug U., et al. Effects of the 5α-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance a prospective clinical study. Steroids. 63:1998;208-213.
37. Nickel J.C., Fradet Y., Boake R.C., et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia results of a 2-year randomized controlled trial (the PROSPECT study). Can Med Assoc J. 155:1996;1251-1259.
38. Kaplan S.A., Holtgrewe H.L., Bruskewitz R., et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology. 57:2001;1073-1077.
39. Burnett A.L. Role of nitric oxide in the physiology of erection. Biol Reprod. 52:1995;485-489.
40. Park K.H., Kim S.W., Kim K.D., et al. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int. 83:1999;327-333.
41. Wasson J.H., Bubolz T.A., Lu-Yao G.L., et al. Transurethral resection of the prostate among medicare beneficiaries 1984 to 1997. J Urol. 164:2000;1212-1215.
42. Emberton M., Neal D.E., Black N., et al. The effect of prostatectomy on symptom severity and quality of life. Br J Urol. 77:1996;233-247.
43. Roehrborn C.G. Standard surgical interventions TURP/TUIP/OPSU. Kirby R., McConnell J., Fitzpatrick J., et al. Textbook of Benign Prostatic Hyperplasia. 1996;341-378 ISIS Medical Media, Oxford.
44. Tscholl R., Largo M., Poppinghaus E., et al. Incidence of erectile impotence secondary to transurethral resection of benign prostatic hyperplasia, assessed by preoperative and postoperative Snap Gauge tests. J Urol. 153:1995;1491-1493.
45. Arai Y., Aoki Y., Okubo K., et al. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function a prospective study. J Urol. 164:2000;1206-1211.
46. Francisca E.A.E., d'Ancona F.C.H., Meuleman E.J.H., et al. Sexual function following high energy microwave thermotherapy results of a randomized controlled study comparing transurethral microwave thermotherapy to transurethral prostatic resection. J Urol. 161:1999;486-490.
47. Larson T., Utz W., Bruskewitz R., et al. Three year results show durable outcome using the Targis™ Microwave System for BPH results of a multi-centered trial. (abstract) Eur Urol. 37:(suppl 2):2000;54.
48. Arai Y., Ishitoya S., Okubo K., et al. Transurethral interstitial laser coagulation for benign prostatic hyperplasia treatment outcome and quality of life. Br J Urol. 78:1996;93-98.
49. Zippe C.D., Jhaveri F.M., Klein E.A., et al. Role of Viagra after radical prostatectomy. Urology. 55:2000;241-245.
50. Burnett A.L. Novel pharmacological approaches in the treatment of erectile dysfunction. World J Urol. 19:2001;57-66.
51. Hale T., Okabe H., Bushfield T., et al. Recovery of erectile function after brief aggressive antihypertensive therapy. J Urol. 168:2002;348-354.
52. Mizusawa H., Hedlund P.S.J.B.J., Sjunnesson J., et al. Enhancement of apomorphine-induced penile erection in the rat by a selective alpha (1D)-adrenoceptor. Br J Pharmacol. 136:2002;701-708.
53. Ramirez-Gil J., Pouyet T., Mayoux E., et al. Enhancement by alfuzosin of the proerectile properties of apomorphine in spontaneous hypertensive rats. J Urol. 167:(suppl 4):2002;281.